Researchers utilized prime editing technology to correct five mutations responsible for alternating hemiplegia of childhood (AHC), a rare neurodevelopmental disorder. The approach demonstrated up to 90% correction in patient-derived cells and substantially mitigated symptoms while extending survival in mouse models. This study marks a milestone in therapeutic gene editing, paving the way for treatments of neurological disorders previously deemed untreatable.